Diltzac

Angina Pectoris, Variant, Atrial Fibrillation, Proteinuria + 11 more

Treatment

6 FDA approvals

20 Active Studies for Diltzac

What is Diltzac

Diltiazem

The Generic name of this drug

Treatment Summary

Diltiazem is a medication used to treat high blood pressure and other cardiovascular conditions like chronic angina and atrial fibrillation. It is classified as a non-dihydropyridine calcium channel blocker, meaning it inhibits the flow of calcium into the heart and blood vessels. Diltiazem is available as an extended-release tablet or intravenous injection and is sold under the brand names Cardizem and Tiazac. It can also be used for off-label treatments such as migraine prevention and rest-related cramps.

Cardizem

is the brand name

image of different drug pills on a surface

Diltzac Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cardizem

Diltiazem

1982

656

Approved as Treatment by the FDA

Diltiazem, commonly known as Cardizem, is approved by the FDA for 6 uses which include Coronary Vasospasm and Coronary Artery Vasospasm .

Coronary Vasospasm

Helps manage Coronary Artery Vasospasm

Coronary Artery Vasospasm

Helps manage Coronary Artery Vasospasm

Anginal Pain

Helps manage Anginal Pain

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Angina Pectoris

Helps manage Anginal Pain

Effectiveness

How Diltzac Affects Patients

Diltiazem is a medication used to reduce blood pressure and relax the blood vessels. It works by blocking calcium in the muscles of the heart and blood vessels to decrease the force and speed of the heart, resulting in lower blood pressure. This drug is most effective in those with higher blood pressure, with a drop of up to 8.6 mmHg after taking doses of 540 mg or higher. It has also been found to increase exercise tolerance in people with chronic stable angina. Studies have also found that using diltiazem can reduce the risk of stroke in hypertensive patients by 25%.

How Diltzac works in the body

Diltiazem works by blocking the slow calcium channels that allow calcium to flow into the cells of your heart and blood vessels. This decreases the amount of calcium in your cells, which relaxes your heart and blood vessels and lowers your blood pressure. It also helps to slow down your heart rate, reducing the oxygen demand of your heart. As a result, this reduces the pain of chronic stable angina and improves your exercise tolerance.

When to interrupt dosage

The suggested dosage of Diltzac is contingent upon the determined condition, such as prophylaxis of migraine headaches, Fissure;Anal and Anginal Pain. Dosage is additionally reliant on the method of delivery outlined in the table beneath.

Condition

Dosage

Administration

Angina Pectoris

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Atrial Fibrillation

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Coronary Vasospasm

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Angina Pectoris, Variant

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Proteinuria

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Hypertensive disease

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Angina, Stable

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Tachycardia, Supraventricular

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Cardiomyopathy, Dilated

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Migraine Disorders

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Diabetic Neuropathy

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Pulmonary Hypertension

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Fissure in Ano

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Muscle Cramp

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Diltzac has ten contraindications and should not be employed in unison with the conditions laid out in the following table.

Diltzac Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

accessory bypass tract

Do Not Combine

accessory bypass tract

Do Not Combine

Bradycardia

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Bradycardia

Do Not Combine

Atrioventricular Block

Do Not Combine

Pulmonary Congestion

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Hypotension

Do Not Combine

There are 20 known major drug interactions with Diltzac.

Common Diltzac Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Diltiazem.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Diltiazem.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Diltiazem.

Alfentanil

Major

The metabolism of Alfentanil can be decreased when combined with Diltiazem.

Amifostine

Major

Diltiazem may increase the hypotensive activities of Amifostine.

Diltzac Toxicity & Overdose Risk

Diltiazem can be toxic if taken in high doses. The toxic dose for mice is between 415 to 740mg/kg when taken orally, and 560 to 810 mg/kg when taken by injection. In dogs, the lethal dose is greater than 50 mg/kg, and in monkeys, 360mg/kg proved to be fatal. People who overdose on diltiazem may experience a slow heartbeat, low blood pressure, heart blockage, or heart failure that can lead to dizziness, lightheadedness, and fatigue. Treatment should depend on the severity of the symptoms and may include atropine, isop

image of a doctor in a lab doing drug, clinical research

Diltzac Novel Uses: Which Conditions Have a Clinical Trial Featuring Diltzac?

228 clinical trials are presently being conducted to investigate the potential of Diltzac to treat Atrial Fibrillation, Coronary Artery Spasm and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

86 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1

Diabetic Neuropathy

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pulmonary Hypertension

31 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Tachycardia, Supraventricular

2 Actively Recruiting

Phase 3, Phase 2

Angina, Stable

0 Actively Recruiting

Angina Pectoris, Variant

0 Actively Recruiting

Angina Pectoris

2 Actively Recruiting

Not Applicable, Phase 4

Cardiomyopathy, Dilated

1 Actively Recruiting

Not Applicable

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

Muscle Cramp

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Coronary Vasospasm

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Fissure in Ano

0 Actively Recruiting

Diltzac Reviews: What are patients saying about Diltzac?

5

Patient Review

2/18/2022

Diltzac for Ventricular Rate Control in Atrial Fibrillation

Diltiazem is the only medication that has ever helped my heart with Atrial Fibrillation. I'm so thankful that my cardiologist prescribed this life-changing medication to me. It's been two years since I started taking it and it has completely changed my life for the better.

5

Patient Review

2/18/2022

Diltzac for Ventricular Rate Control in Atrial Fibrillation

Diltiazem is the only medication that has ever helped my heart with atrial fibrillation. I am extremely grateful to my cardiologist for prescribing this unbelievable good medication for my heart. After 6 weeks of taking it, it changed my life, everything, making my heart to beat normally. It is already 2 years I am taking it . All my gratitude to the scientists, my cardiologist, for giving me back my life!

5

Patient Review

5/30/2019

Diltzac for Supraventricular Cardiac Arrhythmia

I haven't had any issues with this treatment other than feeling a little tired.

5

Patient Review

5/30/2019

Diltzac for Supraventricular Cardiac Arrhythmia

I've been using this medication with few issues. The only downside is that I sometimes feel tired.

4

Patient Review

12/28/2018

Diltzac for Ventricular Rate Control in Atrial Fibrillation

It worked great for me, but I had to stop taking it last year due to changes in my insurance. Almost immediately after stopping the medication, my heart rate issues started up again. But as soon as I started taking the medication again, everything was back to normal.

4

Patient Review

12/28/2018

Diltzac for Ventricular Rate Control in Atrial Fibrillation

Insurance problems led me to stop taking this, and soon after I started having heart rate issues again. However, as soon as I restarted the medication, those effects vanished.

3.7

Patient Review

11/30/2018

Diltzac for High Blood Pressure

I occasionally feel like there's something crawling under my skin, but this treatment has been helping.

3.7

Patient Review

11/30/2018

Diltzac for High Blood Pressure

Sometimes I feel like there's something crawling under my skin.

2.7

Patient Review

8/21/2020

Diltzac for High Blood Pressure

While this drug did help to control my blood pressure and arrhythmia, it was not as effective as beta blockers. When the dosage was increased, I started having migraines on a daily basis which led me to discontinue use of the medication.

2.7

Patient Review

8/21/2020

Diltzac for High Blood Pressure

My blood pressure and arrhythmia weren't as well controlled on this medication as they were on beta blockers. When my dosage was increased, I started having migraines every day, so I had to stop taking the drug.

2.7

Patient Review

11/19/2020

Diltzac for High Blood Pressure

I saw a decrease in my blood pressure after taking this medication, though it is still higher than I'd like. However, I've also developed new problems since starting to take it such as a lump in my rectum and joint pain.

2.7

Patient Review

12/15/2018

Diltzac for Supraventricular Cardiac Arrhythmia

I unfortunately found this treatment made me very drowsy.

2.7

Patient Review

11/19/2020

Diltzac for High Blood Pressure

I take 120mg once a day as directed. While my blood pressure has lowered since starting the medication, it is still high. However, I have also developed a number of new and unpleasant side effects, including but not limited to: a lump in my rectum, dry stools, lower back pain, and joint pain.

2.7

Patient Review

12/15/2018

Diltzac for Supraventricular Cardiac Arrhythmia

I find this medication makes me very drowsy.

2.3

Patient Review

5/19/2019

Diltzac for High Blood Pressure

I didn't have a great experience with this medication. After taking it for just two days, I felt really weak and shaky. All I wanted to do was lay down; it made me feel so lousy.

2.3

Patient Review

3/23/2022

Diltzac for Ventricular Rate Control in Atrial Fibrillation

I experienced a lot of the listed side effects, which were really unpleasant. The worst were fatigue, chest tightness, difficulty swallowing, and swelling in my extremities.

2.3

Patient Review

5/19/2019

Diltzac for High Blood Pressure

I took this medication for two days and found that my legs felt very weak, like rubber. I also had the shakes and felt awful in general. All I wanted to do was lay down; I felt so terrible!

2.3

Patient Review

3/23/2022

Diltzac for Ventricular Rate Control in Atrial Fibrillation

I experienced a lot of the listed side effects, which were really unpleasant. The worst ones for me were fatigue, chest tightness, trouble swallowing/swollen glands in neck, itching, and swelling in hands and feet.

2

Patient Review

1/23/2019

Diltzac for High Blood Pressure

This treatment did nothing to help regulate my blood pressure or heart rate.

2

Patient Review

1/23/2019

Diltzac for High Blood Pressure

I was really disappointed with this treatment. It did nothing to lower my blood pressure or heart rate, even though that's what it's supposed to do.

1.7

Patient Review

10/22/2021

Diltzac for High Blood Pressure

I'm 66 years old, and I started feeling really down and depressed. My blood pressure was high, and I felt lightheaded all the time. After taking this medication, my symptoms only got worse. I won't be taking these tablets anymore.

1.7

Patient Review

10/22/2021

Diltzac for High Blood Pressure

I have been feeling quite down since starting this medication. I'm 66 and I feel like I'm going through menopause with all the mood swings and irritability. My blood pressure hasn't gone down either, and I've been feeling very lightheaded. No more tablets for me.

1.3

Patient Review

10/2/2022

Diltzac for Ventricular Rate Control in Atrial Fibrillation

After getting a cardioversion for afib, I was prescribed Cardizem (diltiazem). However, after only nine days of taking the medication, I stopped because it was having negative effects on my heart rate and blood pressure. It made me incredibly tired to the point where standing was difficult, as well as lightheaded and shaky. The next day after quitting the medication, I felt much better.

1.3

Patient Review

3/25/2019

Diltzac for High Blood Pressure

The dosage of 120 mg caused my blood pressure to go up by 30 units. I experienced horrible side effects like jitters and hypersensitivity. I couldn't even drive!

1.3

Patient Review

10/2/2022

Diltzac for Ventricular Rate Control in Atrial Fibrillation

I was prescribed Cardizem after getting cardioversion for afib. I took it for 9 days, but sometimes after 3 hours of taking the medication, my heart rate and blood pressure would go up instead of down. I also felt extremely tired, lightheaded, and shaky, so I decided to stop taking it. The next day after quitting Cardizem, I felt much better.

1.3

Patient Review

3/25/2019

Diltzac for High Blood Pressure

I had a really bad experience with this drug. I took one 120 mg dose and my blood pressure shot up 30 units. I was incredibly jittery and hyperactive to the point where driving was impossible.

1

Patient Review

1/8/2020

Diltzac for High Blood Pressure

After taking this medication for over a year, I started experiencing pain in my left shoulder, hip, and thigh. I also became lethargic and very tired. I got a rash and sun spots on my face. I stopped taking the medication to see if all these symptoms would go away and they did - thank goodness! This medication also did not help lower my blood pressure.

1

Patient Review

11/22/2019

Diltzac for High Blood Pressure

I took this for a few days to see if it would help lower my blood pressure. Not only did it not work, but I experienced several side effects like coughing, weakness and fatigue, erectile dysfunction, paranoia and depression. Avoid this drug if you can.

1

Patient Review

1/8/2020

Diltzac for High Blood Pressure

I took this for well over a year before I started noticing some serious side effects. Pain in my left shoulder and hip, as well as fatigue and a rash all developed. Once I stopped taking the medication, all of these symptoms went away - which is great! However, it also didn't do anything to help lower my blood pressure.

1

Patient Review

11/22/2019

Diltzac for High Blood Pressure

I tried this for a few days to see if it would help with my blood pressure. Not only was it ineffective, but the side effects were awful. Coughing, weakness, fatigue, and impotence are just a few of the problems I experienced while taking this medication. Additionally, I felt incredibly paranoid and depressed. Do yourself a favor and avoid this drug at all cost.

1

Patient Review

6/13/2022

Diltzac for High Blood Pressure

I was prescribed this for my blood pressure, as I also have Raynauds syndrome. However, after only thirteen days of taking the medication, I broke out in a terrible itchy rash all over my body. My glands were swollen and I felt like my throat was closing up. This prompted a trip to the ER where they confirmed that the rash was indeed related to the medication. I stopped taking the meds immediately and went back to my old prescription. The doctor said that the rash could take up to two weeks to clear up; however, it is by far the worst rash I have ever experienced.

1

Patient Review

6/13/2022

Diltzac for High Blood Pressure

I was put on this medication by my doctor in an effort to help with my Raynaud's Syndrome. However, after only thirteen days of taking the prescribed dosage, I broke out in a terribly itchy rash that covered my entire body. In addition, I also experienced swollen glands and felt like my throat was closing up. This prompted a trip to the ER where they informed me that the rash was likely caused by the medication. Needless to say, I stopped taking the meds and went back to my old prescription. The rash could take up two weeks to clear up; however, even then, it may be worse than anything I
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about diltzac

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Tiadylt the same as diltiazem?

"Tiadylt (diltiazem hydrochloride) inhibits the influx of calcium ions into cells (slow channel blocker)."

Answered by AI

What is the purpose of diltiazem?

"Diltiazem helps to prevent future heart disease, heart attacks and strokes in people with high blood pressure. It can also be used to prevent chest pain caused by angina and to help heal anal fissures."

Answered by AI

What are the side effects of taking diltiazem?

"The following are symptoms of the flu: dizziness or lightheadedness, flushing, headache, weakness, slow heartbeat, vomiting, diarrhea, constipation."

Answered by AI

Is it better to take diltiazem in the morning or at night?

"The traditional way of taking anti-ischemic medication in the morning may not be as effective as taking it before bedtime. This is because there is an increased risk of myocardial ischemia in the morning hours."

Answered by AI

Clinical Trials for Diltzac

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of the FSU TMH Family Practice Residency Program in Tallahassee, United States.

Cannabidiol for Diabetic Neuropathy

40 - 70
All Sexes
Tallahassee, FL

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Phase 1 & 2
Waitlist Available

the FSU TMH Family Practice Residency Program

Have you considered Diltzac clinical trials?

We made a collection of clinical trials featuring Diltzac, we think they might fit your search criteria.
Go to Trials
Image of Grand Island Pain Relief Center in Grand Island, United States.

BurstDR Spinal Cord Stimulation for Diabetic Neuropathy

18+
All Sexes
Grand Island, NE

This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy (PDN). Adults with confirmed PDN will undergo a one-week temporary SCS trial, and those achieving meaningful improvement (≥50% reduction in average pain on the Visual Analog Scale) will proceed to permanent implantation. Outcomes will be assessed at baseline, end of trial, and at 1-, 3-, and 6-month follow-up visits using validated instruments including VAS, DN4, DQoL, PSQ-3, the Patient Global Impression of Change, and the Clinician Global Impression of Change. All procedures follow standard clinical practice for SCS therapy. The study aims to characterize real-world effectiveness, patient-reported outcomes, feasibility of implementation, and device-related safety in a rural PDN population.

Waitlist Available
Has No Placebo

Grand Island Pain Relief Center

TriCity Research Center

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Diltzac clinical trials?

We made a collection of clinical trials featuring Diltzac, we think they might fit your search criteria.
Go to Trials
Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Diltzac clinical trials?

We made a collection of clinical trials featuring Diltzac, we think they might fit your search criteria.
Go to Trials